Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 5:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 618 matching trials from the live ClinicalTrials.gov search.
Conditions
HIV Infections
Interventions
Raltegravir, Darunavir, Ritonavir, Tenofovir/Emtricitabine
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Dallas, Texas
Conditions
Healthy
Interventions
bococizumab PFS:Pfizer, bococizumab PFS: BIP, bococizumab PFP
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
470 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
5
States / cities
Hollywood, Florida • South Miami, Florida • Saint Paul, Minnesota + 1 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of APX001 High-load and Low-load Tablets

NCT05491733
Conditions
Invasive Fungal Infections
Interventions
APX001, APX001A
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
Interventions
Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel, Mosunetuzumab, Patient Observation, Polatuzumab Vedotin, Positron Emission Tomography, Tisagenlecleucel
Biological · Procedure · Drug + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
95
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more
Conditions
Multiple Myeloma
Interventions
Elranatamab, Lenalidomide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
24
States / cities
Gilbert, Arizona • Los Angeles, California • Santa Monica, California + 14 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug Interaction Study

NCT00646776
Conditions
Antivirals/HIV
Interventions
Rifabutin, Rifabutin + Atazanavir + Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Conditions
Healthy Volunteer
Interventions
danoprevir, darunavir, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Standard of Care Chemotherapy
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 12 more
Conditions
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Interventions
PF-08634404, Chemotherapy, Nivolumab
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
83
States / cities
Atascadero, California • Burbank, California • Encino, California + 68 more
Conditions
Neoplasms, Breast
Interventions
lapatinib, carboplatin, trastuzumab, paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
3
States / cities
La Jolla, California • Indianapolis, Indiana • Greensboro, North Carolina
Conditions
Acute Ischemic Stroke, Cerebral Stroke
Interventions
Drug: Normal Saline, Sovateltide
Drug
Lead sponsor
Pharmazz, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
16
States / cities
Tucson, Arizona • Carmichael, California • Oxnard, California + 11 more
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 (Moderate AH), DUR-928 (Severe AH)
Drug
Lead sponsor
Craig James McClain
Other
Eligibility
21 Years to 67 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Hepatitis B Infection, Malignant Solid Neoplasm
Interventions
Best Practice, Entecavir, Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate
Other · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
192
States / cities
Fort Smith, Arkansas • Anaheim, California • Antioch, California + 140 more
Completed Not applicable Interventional Accepts healthy volunteers

Gender-Responsive Drug Use Treatment for Juvenile Justice Girls

NCT02293057
Conditions
Drug Use
Interventions
VOICES Group, Girl Health Group
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years to 24 Years · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Francisco, California
Conditions
Urinary Tract Infections, Pelvic Organ Prolapse, Urinary Incontinence
Interventions
Nitrofurantoin Prophylaxis/Placebo, Cranberry capsules
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults

NCT01739231
Conditions
Diarrhea
Interventions
ACE527, dmLT, CeraVacx placebo, H10407 challenge strain
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 50 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 3 Interventional Results available

Cross-linking for Corneal Ulcers Treatment Trial

NCT02570321
Conditions
Corneal Ulcer, Infectious Keratitis, Bacterial Ulcer, Fungal Ulcer
Interventions
Corneal Cross-linking, Anti Fungal Drug
Procedure · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

NCT03227471
Conditions
Cystic Fibrosis
Interventions
IVA, TEZ/IVA, VX-445, Matched Placebo, TEZ, VX-561
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability Study of Lisinopril Tablets, 10 mg

NCT01375244
Conditions
Healthy
Interventions
Lisinopril, Zestril
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Knee Arthropathy
Interventions
ACB + IPACK block with injection of local anesthetic, ACB + IPACK block without injection
Other
Lead sponsor
University of Louisville
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Glioblastoma Multiforme
Interventions
VBI-1901, Carmustine, Lomustine
Biological · Drug
Lead sponsor
VBI Vaccines Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 8 more
Recruiting Phase 2 Interventional Accepts healthy volunteers

4-aminopyridine for Skin Wound Healing

NCT06333171
Conditions
Wounds, Wound of Skin, Wound Heal, Wounds and Injuries
Interventions
4-Aminopyridine, Placebo
Drug · Other
Lead sponsor
John Elfar
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
Interventions
Avelumab, Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
271
States / cities
Phoenix, Arizona • Auburn, California • Berkeley, California + 214 more